Northwest Biotherapeutics (NWBO) Asset Utilization Ratio (2011 - 2026)

Northwest Biotherapeutics' Asset Utilization Ratio history runs 16 years deep, the most recent figure standing at 0.02 for Q1 2026.

• On a quarterly basis, Asset Utilization Ratio fell 65.84% year-over-year to 0.02 in Q1 2026; TTM through Mar 2026 was 0.02, a 65.84% decrease from a year earlier, with the FY2025 full-year figure at 0.03, down 49.61% from the prior year.
• Asset Utilization Ratio declined to 0.02 in Q1 2026 per NWBO's latest filing, from 0.02 in the prior quarter.
• Across five years, Asset Utilization Ratio topped out at 0.07 in Q3 2023 and bottomed at 0.02 in Q1 2026.
• The 5-year median for Asset Utilization Ratio is 0.05 (2024), against an average of 0.05.
• Across the five-year window, Asset Utilization Ratio soared 103.84% in 2023 and plunged 65.84% in 2026, its largest moves.
• Year by year, Asset Utilization Ratio stood at 0.05 in 2022, then grew by 20.72% to 0.07 in 2023, then decreased by 24.25% to 0.05 in 2024, then plunged by 50.06% to 0.02 in 2025, then declined by 24.66% to 0.02 in 2026.
• Per Business Quant, the three latest NWBO Asset Utilization Ratio figures stand at 0.02 (Q1 2026), 0.02 (Q4 2025), and 0.03 (Q3 2025).